Massachusetts-based AI drug discovery startup Valo Health has acquired New York-based biotechnology company TARA Biosystems. The terms and financial details of the transaction were not disclosed.
The transaction will integrate TARA’s proprietary cardiac disease platform with in-vitro cardiac disease models into Valo’s AI-driven computational platform Opal—which incorporates large sets of patient data—to create an end-to-end drug discovery and development platform exclusively for cardiovascular diseases.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.